Inari Medical [NARI] vs Abbott Laboratories [ABT] Detailed Stock Comparison

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Inari Medical wins in 4 metrics, Abbott Laboratories wins in 12 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricInari MedicalAbbott LaboratoriesBetter
P/E Ratio (TTM)-2,665.6716.89Inari Medical
Price-to-Book Ratio10.754.63Abbott Laboratories
Debt-to-Equity Ratio7.5326.50Inari Medical
PEG Ratio571.210.46Abbott Laboratories
EV/EBITDA-176.1421.02Inari Medical
Profit Margin (TTM)-13.68%32.43%Abbott Laboratories
Operating Margin (TTM)-4.34%19.73%Abbott Laboratories
EBITDA Margin (TTM)N/A19.73%N/A
Return on Equity-17.72%30.93%Abbott Laboratories
Return on Assets (TTM)-3.21%6.62%Abbott Laboratories
Free Cash Flow (TTM)N/A$6.35BN/A
Dividend YieldN/A1.28%N/A
1-Year ReturnN/A15.17%N/A
Price-to-Sales Ratio (TTM)8.155.43Abbott Laboratories
Enterprise Value$4.60B$240.70BAbbott Laboratories
EV/Revenue Ratio8.015.58Abbott Laboratories
Gross Profit Margin (TTM)87.06%56.44%Inari Medical
Revenue per Share (TTM)$10$25Abbott Laboratories
Earnings per Share (Diluted)$-1.35$7.97Abbott Laboratories
Beta (Stock Volatility)1.030.70Abbott Laboratories
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Inari Medical vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Inari Medical0.00%0.06%0.59%56.90%96.87%54.38%
Abbott Laboratories-0.63%0.47%1.16%0.03%7.11%17.89%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Inari MedicalN/AN/AN/AN/AN/AN/A
Abbott Laboratories15.17%32.53%21.95%216.77%424.26%553.67%

News Based Sentiment: Inari Medical vs Abbott Laboratories

Inari Medical

News sentiment data is not available for Inari Medical at this time.

Abbott Laboratories

News based Sentiment: POSITIVE

Abbott Laboratories delivered strong Q2 earnings and raised guidance, leading to positive analyst revisions and continued institutional investment. While some valuation models suggest the stock may be overvalued, the overall narrative is positive, driven by strong financial performance and a promising product pipeline.

View Abbott Laboratories News Sentiment Analysis

Performance & Financial Health Analysis: Inari Medical vs Abbott Laboratories

MetricNARIABT
Market Information
Market Cap i$4.68B$234.39B
Market Cap CategoryMid capMega cap
10 Day Avg. Volume i1,052,4785,683,430
90 Day Avg. Volume i3,170,3695,498,563
Last Close$79.97$133.74
52 Week Range$36.73 - $79.99$110.86 - $141.23
% from 52W High-0.02%-5.30%
All-Time High$79.97 (Feb 19, 2025)$142.60 (Dec 27, 2021)
% from All-Time High0.00%-6.21%
Growth Metrics
Quarterly Revenue Growth0.21%0.07%
Quarterly Earnings GrowthN/A0.37%
Financial Health
Profit Margin (TTM) i-0.14%0.32%
Operating Margin (TTM) i-0.04%0.20%
Return on Equity (TTM) i-0.18%0.31%
Debt to Equity (MRQ) i7.5326.50
Cash & Liquidity
Book Value per Share (MRQ)$7.44$29.05
Cash per Share (MRQ)$1.91$4.18
Operating Cash Flow (TTM) i$14.18M$9.04B
Levered Free Cash Flow (TTM) i$86.61M$5.92B
Dividends
Last 12-Month Dividend Yield iN/A1.28%
Last 12-Month Dividend iN/A$1.69

Valuation & Enterprise Metrics Analysis: Inari Medical vs Abbott Laboratories

MetricNARIABT
Price Ratios
P/E Ratio (TTM) i-2,665.6716.89
Forward P/E i571.2126.08
PEG Ratio i571.210.46
Price to Sales (TTM) i8.155.43
Price to Book (MRQ) i10.754.63
Market Capitalization
Market Capitalization i$4.68B$234.39B
Enterprise Value i$4.60B$240.70B
Enterprise Value Metrics
Enterprise to Revenue i8.015.58
Enterprise to EBITDA i-176.1421.02
Risk & Other Metrics
Beta i1.030.70
Book Value per Share (MRQ) i$7.44$29.05

Financial Statements Comparison: Inari Medical vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)NARIABT
Revenue/Sales i$153.39M$10.36B
Cost of Goods Sold i$19.85M$4.47B
Gross Profit i$133.54M$5.89B
Research & Development i$29.43M$716.00M
Operating Income (EBIT) i$-6.66M$1.69B
EBITDA i$-304,000$2.66B
Pre-Tax Income i$-12.67M$1.78B
Income Tax i$5.70M$453.00M
Net Income (Profit) i$-18.37M$1.33B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)NARIABT
Cash & Equivalents i$41.14M$6.53B
Total Current Assets i$263.39M$23.15B
Total Current Liabilities i$148.78M$13.00B
Long-Term Debt i$31.15M$12.74B
Total Shareholders Equity i$434.76M$49.06B
Retained Earnings i$-122.40M$47.72B
Property, Plant & Equipment i$66.83MN/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)NARIABT
Operating Cash Flow iN/A$1.42B
Capital Expenditures iN/A$-484.00M
Free Cash Flow iN/A$933.00M
Debt Repayment iN/A$-1.00B
Common Stock Repurchase iN/A$-280.00M

Short Interest & Institutional Ownership Analysis

MetricNARIABT
Shares Short iN/A18.07M
Short Ratio iN/A3.68
Short % of Float iN/A0.01%
Average Daily Volume (10 Day) i1,052,4785,683,430
Average Daily Volume (90 Day) i3,170,3695,498,563
Shares Outstanding i57.76M1.73B
Float Shares i53.34M1.73B
% Held by Insiders i0.09%0.01%
% Held by Institutions i0.96%0.81%

Dividend Analysis & Yield Comparison: Inari Medical vs Abbott Laboratories

MetricNARIABT
Last 12-Month Dividend iN/A$1.69
Last 12-Month Dividend Yield iN/A1.28%
3-Year Avg Annual Dividend iN/A$1.92
3-Year Avg Dividend Yield iN/A0.49%
3-Year Total Dividends iN/A$5.77
Ex-Dividend DateN/AJan 15, 2025